Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST-003
- Development stage
- Unknown
- Lead developer
- SteroTherapeutics
- Modality
- Small Molecules
01
Overview
ST-003 is a small molecule drug candidate being developed by SteroTherapeutics for the treatment of Primary Sclerosing Cholangitis (PSC) and associated Inflammatory Bowel Disease (IBD). It targets Galectin-1 (Gal1) and Galectin-2 (Gal2), which are members of a protein family that binds beta-galactoside sugars and mediates various inflammatory and fibrotic processes. By inhibiting these galectins, ST-003 aims to reduce cholangiocyte proliferation and fibrogenesis in the liver and gastrointestinal tract. The drug has received Orphan Drug Designation from the U.S. FDA and is currently in Phase 1 clinical development.
- Other names
- galanin receptor antagonist (descriptive, not formal)
02
Targets
GALR2 (Galanin receptor 2)
Beyond the preview
Go deeper on ST-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST-003.